Haemonetics (HAE) | Stock Overview & Key Data
Haemonetics Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $142.11 on February 8, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Haemonetics
HAE
|
2.77B Mid-cap | -1.91% | 19.09% | 0.38% | -19.57% | -17.63% | 0.15% | -23.06% | 23.11% | 138.01% | 105.17% | 166.65% |
| 160.70B Large-cap | 1.53% | -0.63% | -23.43% | -30.57% | -29.95% | -35.92% | -17.85% | -21.68% | 118.48% | 249.25% | 313.73% | |
|
Stryker
SYK
|
126.25B Large-cap | -3.58% | 1.42% | -23.29% | -19.39% | -15.27% | -20.27% | 9.63% | 21.15% | 168.66% | 406.79% | 583.29% |
|
Masimo
MASI
|
9.36B Mid-cap | 0.00% | 0.32% | 1.95% | 29.47% | 40.33% | 9.82% | 9.28% | -15.51% | 257.33% | 509.04% | 791.36% |
|
Bio-Rad
BIO.B
|
8.08B Mid-cap | 13.73% | 1.57% | 13.11% | -2.11% | -2.11% | 21.62% | -18.04% | -49.03% | 106.20% | 145.92% | 353.96% |
| 7.60B Mid-cap | -0.15% | 18.22% | 8.79% | -4.84% | -0.14% | 37.70% | -16.08% | -46.24% | 110.71% | 155.96% | 366.11% |
Ownership & Short Interest
Calculate Your Haemonetics Investment Returns
Long-Term Investment Performance Analysis
Haemonetics stock price in May 2016 was $28.49, A $1,000.00 lump sum investment in Haemonetics made 10 years ago would be worth approximately $2,312.39 today, representing a strong return of 131.24%. This translates to an annualized return (CAGR) of 8.74%.
10 Years Investment Scenario (May 2016 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is HAE's 52-week high and low?
- In the last 52 weeks, Haemonetics reached a high of $87.32 (on N/A) and a low of $47.32 (on September 26, 2025).
- What is the market cap and P/E ratio for HAE?
- Curious about Haemonetics's size and valuation? Its market capitalization stands at 2.77B. When it comes to valuation, the P/E ratio (trailing twelve months) is 16.42, and the forward P/E (looking ahead) is 11.27.
- Does HAE pay dividends? If so, what's the yield?
- As for dividends, Haemonetics isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Haemonetics's main competitors or similar companies to consider before investing?
When looking at Haemonetics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Abbott Laboratories
ABT160.70B Healthcare Medical Devices -35.92% -17.85% Stryker
SYK126.25B Healthcare Medical Devices -20.27% 9.63% Masimo
MASI9.36B Healthcare Medical Devices 9.82% 9.28% Bio-Rad
BIO.B8.08B Healthcare Medical Devices 21.62% -18.04% Bio-Rad Laboratories
BIO7.60B Healthcare Medical Devices 37.70% -16.08% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Haemonetics Corporation? (e.g., ROE, Debt/Equity)
- To get a sense of Haemonetics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 19.30%, the Debt to Equity ratio from the most recent quarter is 134.40, and its Gross Profit Margin stands at 59.71%.
- What is the recent revenue and earnings growth for HAE?
- Looking at Haemonetics's growth, its revenue over the trailing twelve months (TTM) was $1B. Compared to the same quarter last year (YoY), quarterly revenue grew by -2.70%, and quarterly earnings saw a YoY growth of 19.30%.
- How much of HAE stock is held by insiders and institutions?
- Wondering who owns Haemonetics stock? Company insiders (like executives and directors) hold about 1.19% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 115.88%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.